Management

Per Andersson

Chief Executive Officer

Chief Executive Officer at Xspray Pharma since 2006
Born 1967

Per has a background as Science Director at Gyros Protein Therapeutics AB, where he developed a completely new ground-breaking technology into something that is now profitable products. He has over 200 patents as an inventor and successfully worked in patent strategy for more than 25 years. Previously, he worked as a senior scientist at Cytiva AB, where he focused on technological innovation. Per is co-author of over 30 scientific publications.

Education: Ph.D. in Analytical Chemistry, Stockholm university

Other current activities: CEO of Xspray Pharma Inc., Chairman of the board of Robotic Lawn Care Sweden AB and Xspray Pharma Futurum AB, and deputy board member in Journeyman Stockholm AB

Holdings: 199,560 shares and 310,923 options of which 103,641 warrants and 207,282 employee stock options.

Independent in relation to the larger shareholders but not in relation to the company

Niklas Adenborg

Chief Financial Officer since 2024

Born 1992

Niklas has extensive finance and auditing experience, and has previously been auditor at KPMG. Niklas joined Xspray Pharma 2019 and has previous held roles as Financial Controller and Finance Director.

Education: Bachelor of Science in Business and Economics, Uppsala University

Other current activities: Other current activities: Chairman of the Board of Päron AB Board Member of Brf Flöjtblåsaren 7

Holdings in the Company: 1,721 shares and 50,250 options of which 16,750 warrants and 33,500 employee stock options

Independent in relation to major shareholders but not in relation to the Company

Mikael von Euler

Chief Medical Officer since 2023

Born 1953

Mikael is an oncologist with more than 35 years of experience of drug development in the pharmaceutical industry. He has served in several senior global roles in big pharma companies such as Cluster Head for the Her2 area (Herceptin, pertuzumab, T-DM1) at Roche/Genentech, Vice President of Oncology Europe at GlaxoSmithKline and Global Product Director of Arimidex/Nolvadex at AstraZeneca. For the past 15 years he has been supporting small and start-up companies in senior roles, as board member, and as an independent consultant.

Education: Education: Mikael received his MD and PhD from the Karolinska Institute in Stockholm, Sweden. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK.

Other current activities: Other current activities: Owner and CEO of M von Euler Consulting AB. Board member of Dicot Pharma AB, Annexin Pharmaceuticals AB and Spago Nanomedical AB.

Holdings in the company: 3,730 shares.

Independent in relation to major shareholders but not in relation to the Company

Linda Glimberg

Chief Operating Officer

Chief Operating Officer at Xspray Pharma since 2024
Born 1974

Linda has worked as a lawyer for more than 25 years of which more than 15 years as an in-house counsel at international companies. Since 2018 she has been running her own consultancy firm providing business legal advice, focusing on the life science sector. She has held various leading positions at AstraZeneca, Husqvarna and Keolis.

Education: Master of Laws (LLM), Uppsala University. Master of Laws (LLM) Cambridge University, England

Other current activities: Owner and Board Member of Glimberg Holding AB and Glimberg Consulting AB, Board Member of Robotic Lawn Care Sweden AB.

Holdings in the Company: 2,470 shares via Company and 10,026 options of which 3,342 warrants and 6,684 employee stock options.

Independent in relation to major shareholders but not in relation to the Company.